Literature DB >> 12473212

Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant.

D Fowler1, J Hou, J Foley, F Hakim, J Odom, K Castro, C Carter, E Read, J Gea-Banacloche, C Kasten-Sportes, L Kwak, W Wilson, B Levine, C June, R Gress, M Bishop.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12473212     DOI： 10.1080/146532402320776053

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


× No keyword cloud information.
  2 in total

1.  Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

Authors:  Nancy M Hardy; Vicki Fellowes; Jeremy J Rose; Jeanne Odom; Stefania Pittaluga; Seth M Steinberg; Bazetta Blacklock-Schuver; Daniele N Avila; Sarfraz Memon; Roger J Kurlander; Hahn M Khuu; Maryalice Stetler-Stevenson; Esther Mena; Andrew J Dwyer; Bruce L Levine; Carl H June; Ran Reshef; Robert H Vonderheide; Ronald E Gress; Daniel H Fowler; Frances T Hakim; Michael R Bishop
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

2.  Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.

Authors:  Nancy M Hardy; Miriam E Mossoba; Seth M Steinberg; Vicki Fellowes; Xiao-Yi Yan; Frances T Hakim; Rebecca R Babb; Daniele Avila; Juan Gea-Banacloche; Claude Sportès; Bruce L Levine; Carl H June; Hahn M Khuu; Ashley E Carpenter; Michael C Krumlauf; Andrew J Dwyer; Ronald E Gress; Daniel H Fowler; Michael R Bishop
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.